The European Medical Association (EMA) granted NeuroSense Therapeutics, a clinical stage drug development company, orphan drug designation today (1/12) for PrimeC, a unique combination drug for treatment of Amyotrophic Lateral Sclerosis (ALS). The U.S. Food and Drug Administration (FDA) had already granted PrimeC orphan drug designation in 2020. CEO of NeuroSense Therapeutics, Alon Ben-Noon, stated, “We are encouraged by these accomplishments and are looking forward to expediting the development of PrimeC in Europe, the US and globally.  Our team at NeuroSense is dedicated to bringing PrimeC to patients suffering from the debilitating disease that is ALS.”

Read more here.

More on: